$-0.08
(Market cap
$274 Mln
Revenue (TTM)
$232 Mln
P/E Ratio
--
P/B Ratio
10.1
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.8 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
45.5
-
Debt to Equity
1.3
-
Book Value
$--
-
EPS
$-0.1
-
Face value
--
-
Shares outstanding
268,258,243
10 Years Aggregate
CFO
$-892.97 Mln
EBITDA
$-1,358.90 Mln
Net Profit
$-1,514.65 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Akebia Ther (AKBA)
| -41.9 | -33.1 | -28.6 | -69.1 | -5.0 | -22.8 | -20.2 |
|
BSE Sensex
| -11.8 | -2.9 | -8.2 | -8.4 | 6.1 | 7.5 | 10.8 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Akebia Ther (AKBA)
| -15.3 | 52.7 | 114.9 | -74.5 | -19.3 | -55.7 | 14.3 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Akebia Ther (AKBA)
|
0.9 | 273.6 | 232.4 | -20.5 | 0.8 | -59.5 | -- | 10.1 |
| 71.3 | 10,974.2 | 622.0 | -300.9 | -25.7 | -61.1 | -- | 18.1 | |
| 216.4 | 13,845.5 | 867.5 | 506.6 | -2.8 | -- | 25.5 | 25.6 | |
| 71.3 | 10,421.8 | 105.8 | -829.6 | -715.0 | -- | -- | 60.3 | |
| 48.8 | 12,688.4 | 2,375.5 | 833.4 | 40.8 | 40.7 | 16.7 | 6.5 | |
| 129.0 | 17,196.9 | 1,080.2 | -433.2 | -39.8 | -- | -- | 55.7 | |
| 294.4 | 9,110.1 | 417.3 | 225.0 | 42.8 | 18.6 | 41.4 | 7.1 | |
| 462.3 | 11,464.9 | 1,132.5 | -309.4 | -25.5 | -52.9 | -- | 22.4 | |
| 444.9 | 12,769.3 | 2,678.3 | 460.4 | 21.1 | 103.2 | 28.2 | 20.4 | |
| 265.7 | 9,756.7 | 0.0 | -326.5 | -- | -37.2 | -- | 7.0 |
Shareholding Pattern
View DetailsAbout Akebia Ther (AKBA)
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl... hydroxylase, for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD. The company is also developing AKB-9090, which is in Phase 2 clinical trial for treating cardiac surgery-related acute kidney injury and acute respiratory distress syndrome; and AKB-10108 for the treatment of retinopathy of prematurity in neonates. The company has license and collaboration agreements with Tanabe Pharma Corporation for the development and commercialization of Vafseo in Japan and other Asian countries; Vafseo License and Collaboration Agreements; CSL Vifor Agreements; Averoa License Agreement; License Agreement with Panion & BF Biotech, Inc.; Cyclerion Therapeutics License Agreement; and Q32 Asset Purchase Agreement. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts. Read more
-
CEO, President, Interim Principal Financial Officer & Director
Mr. John P. Butler MBA
-
CEO, President, Interim Principal Financial Officer & Director
Mr. John P. Butler MBA
-
Headquarters
Cambridge, MA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Akebia Ther (AKBA)
What is the current share price of Akebia Ther (AKBA) Today?
The share price of Akebia Ther (AKBA) is $0.94 (NASDAQ) as of 02-Jun-2026 15:36 EDT. Akebia Ther (AKBA) has given a return of -4.95% in the last 3 years.
What is the current PB & PE ratio of Akebia Ther (AKBA)?
Since, TTM earnings of Akebia Ther (AKBA) is negative, P/E ratio is not available.
The P/B ratio of Akebia Ther (AKBA) is 10.09 times as on 29-May-2026, a 127 premium to its peers’ median range of 4.44 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-79.93
|
13.10
|
|
2024
|
-5.99
|
-8.45
|
|
2023
|
-4.55
|
-7.72
|
|
2022
|
-1.13
|
20.30
|
|
2021
|
-1.62
|
5.36
|
What is the 52 Week High and Low of Akebia Ther (AKBA)?
The 52-week high and low of Akebia Ther (AKBA) are Rs 4.08 and Rs 0.88 as of 03-Jun-2026.
What is the market cap of Akebia Ther (AKBA)?
Akebia Ther (AKBA) has a market capitalisation of $ 274 Mln as on 29-May-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Akebia Ther (AKBA)?
Before investing in Akebia Ther (AKBA), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.